TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Entrada Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$4.82+0.45 (+10.30%)
Close on Oct 19, 2026
- Market cap
- $203.51M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
-621.1%
Net margin
-565.5%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -87.9% | – | – | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 93.1% | -39.1% | |
| Return on assets | – | – | -31.8% | |
| Current ratio | – | 11.89 | 12.53 | |
| Capex to revenue | – | – | 4.1% | |
| Diluted shares | – | 1M | 41M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Entrada Therapeutics generated $454.52M from operations and spent $17.28M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$454.52M
Used
$17.28M
Capital expenditure$17.28M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-565.5%
×Asset turnover0.06×
×Equity multiplier1.23×
=Return on equity, FY2025-39.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -565.5% | 0.06× | 1.23× | -39.1% |
| FY2024 | 31.1% | 0.42× | 1.48× | 19.6% |
| FY2023 | -5.2% | 0.36× | 1.59× | -2.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$143.75M
- Cash generatingOperating cash flow above zero-$128.51M
- Return on assets improvedROA up on the prior year14.0% → -27.3%
- Earnings backed by cashOperating cash flow above net income-$128.51M vs -$143.75M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose11.15 → 12.53
- No dilutionShare count did not rise39M → 41M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.45 → 0.05